2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
3
Neoplasms
3
Carcinoma, Hepatocellular
3
Neoplasm Metastasis
2
Glioma
2
Glioblastoma
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Nasopharyngeal Carcinoma
1
Colorectal Neoplasms
1
Colorectal Cancer Metastatic
1
Carcinosarcoma
1
Camurati-Engelmann Syndrome
1
Breast Neoplasms
1
Interventions
Bevacizumab
19
Capecitabine
15
Oxaliplatin
11
Irinotecan
11
Cetuximab
11
Fluorouracil
10
Leucovorin
8
aflibercept
7
Panitumumab
6
trifluridine tipiracil drug combination
4
Nivolumab
4
sintilimab
3
regorafenib
3
Ipilimumab
3
Vemurafenib
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
HMPL-013
2
Folfox protocol
2
Drug Therapy
2
tremelimumab
1
spartalizumab
1
raltitrexed
1
pembrolizumab
1
monoclonal antibody YYB-101
1
masitinib
1
irinotecan sucrosofate
1
glucopyranosyl lipid-A
1
folfirinox
1
durvalumab
1
camrelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Cancer Metastatic
×
LY-2157299
×
Clear all
NCT03470350
2019-07-24
EORTC1615
The Netherlands Cancer Institute
Phase 1/2
Withdrawn